Should You Discontinue the PPI?
Yes, you should strongly consider discontinuing the PPI in this patient with functional EGJOO who demonstrates no acid exposure on pH testing while on therapy. The absence of pathologic acid exposure indicates no ongoing GERD requiring acid suppression, and functional EGJOO itself is not an indication for PPI therapy 1.
Clinical Reasoning
Why Discontinuation is Appropriate
The 2022 AGA guidelines are clear: the decision to discontinue PPIs should be based solely on the lack of an indication for PPI use 1. Your patient has:
- No acid exposure on pH testing - This objectively demonstrates no pathologic GERD
- Functional EGJOO - This is a motility disorder, not an acid-mediated condition
- No definitive indication for chronic PPI therapy per the AGA indications table 1
Functional EGJOO does not appear in the AGA's list of definitive or conditional indications for long-term PPI use. The conditions that warrant continued PPI therapy include Barrett's esophagus, severe erosive esophagitis (LA grade C/D), peptic strictures, and high GI bleeding risk - none of which apply here 1.
Supporting Evidence from pH Monitoring
Recent high-quality research demonstrates that patients with 0 days of acid exposure time (AET) >4.0% have a 10-times increased odds of successfully discontinuing PPIs 2. Your patient's negative pH study while on PPI strongly suggests they will tolerate discontinuation well. The 2021 clinical trial by Yadlapati et al. showed that ambulatory reflux monitoring effectively guides PPI discontinuation decisions, with 34% of patients successfully stopping PPIs when testing showed no pathologic acid exposure 2.
Discontinuation Strategy
Choose Your Approach
Either tapering or abrupt discontinuation are acceptable options 1. The evidence shows no significant difference in success rates (31% vs 22% for tapered vs abrupt at 6 months) 1.
For tapering: Consider daily PPI → every other day for 2-3 weeks → discontinue
For abrupt discontinuation: Stop immediately with rescue therapy available
Critical Patient Counseling
Warn about rebound acid hypersecretion (RAHS) - The patient may experience upper GI symptoms for up to 2 months after stopping, which does NOT necessarily indicate they need to resume continuous PPI therapy 1. This is a physiologic phenomenon from parietal cell hyperplasia that regresses over 2-6 months 1.
Provide rescue options:
- On-demand PPIs (not daily)
- H2-receptor antagonists as needed
- Antacids for breakthrough symptoms
Red Flags for Re-evaluation
Severe persistent symptoms lasting >2 months after discontinuation may suggest either:
- A continuing indication for PPI therapy that was missed
- A non-acid-mediated cause of symptoms requiring different management 1
Common Pitfalls to Avoid
Don't continue PPIs out of fear of adverse events - The decision should be based on indication, not concern about potential complications 1
Don't confuse RAHS symptoms with treatment failure - Transient symptoms in the first 2 months are expected and manageable with lower-potency options 1
Don't assume functional EGJOO requires acid suppression - This is a motility disorder that may require entirely different management approaches (dietary modification, potential EGJ disruption therapy if truly obstructive) 3, 4
Don't restart continuous PPI for every symptom - Use on-demand or rescue therapy first 1
The Bottom Line
Your patient has objective evidence (negative pH testing) showing no acid-mediated disease and a diagnosis (functional EGJOO) that is not an indication for PPI therapy. Discontinue the PPI using either tapering or abrupt cessation, counsel about expected RAHS, provide rescue medications, and reassess only if severe symptoms persist beyond 2 months 1, 2.